Literature DB >> 3126920

HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort.

P Simmonds1, F A Lainson, R Cuthbert, C M Steel, J F Peutherer, C A Ludlam.   

Abstract

Sequential serum samples from 18 haemophiliac patients exposed simultaneously to human immunodeficiency virus type 1 (HIV 1) in early 1984 were tested retrospectively for serological markers of infection. Assay for total antibodies to HIV established that the time to seroconversion might be as long as 110 days after exposure to contaminated factor VIII; serum samples were also tested by Western blotting, by enzyme linked immunosorbent assay (ELISA) for specific antibodies to envelope and core proteins, and for p24 antigen by two assay systems during the two years after infection. The studies showed that five of the 12 patients for whom serum samples obtained between exposure and seroconversion were available had transient p24 antigenaemia. Although amounts of total antibody to HIV and of antibodies to envelope proteins rose continuously during the two years of the study, amounts of antibody to the core protein were variable and tended to decline in patients who became symptomatic. Two patients had persistent p24 antigenaemia that began four months after seroconversion; these patients remained asymptomatic. One patient who developed the acquired immune deficiency syndrome (AIDS) had transient antigenaemia at the time of seroconversion but failed to show any antigen for the rest of the study; progression to AIDS was accompanied by an increase in antibodies to envelope proteins. Much of the variability in the course of infection with HIV must represent the differences in the susceptibility of the patients to infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126920      PMCID: PMC2545233          DOI: 10.1136/bmj.296.6622.593

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  10 in total

1.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs.

Authors:  J P Allain; Y Laurian; D A Paul; D Senn
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

4.  Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.

Authors:  J M Lange; R A Coutinho; W J Krone; L F Verdonck; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

5.  Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients.

Authors:  S K Arya; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

6.  Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII.

Authors:  C A Ludlam; J Tucker; C M Steel; R S Tedder; R Cheingsong-Popov; R A Weiss; D B McClelland; I Philp; R J Prescott
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

7.  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

Authors:  B Safai; M G Sarngadharan; J E Groopman; K Arnett; M Popovic; A Sliski; J Schüpbach; R C Gallo
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

8.  Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.

Authors:  W J Morrow; M Wharton; R B Stricker; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1986-09

9.  Evaluation of six enzyme immunoassays for antibody against human immunodeficiency virus.

Authors:  H W Reesink; P N Lelie; J G Huisman; W Schaasberg; M Gonsalves; C Aaij; I N Winkel; J A van der Does; A C Hekker; J Desmyter
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

10.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

  10 in total
  15 in total

Review 1.  The clinical prognosis of HIV-1 infection: a review of 32 follow-up studies.

Authors:  G S Cooper; D J Jeffers
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

2.  HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.

Authors:  R S Remis; M V O'Shaughnessy; C Tsoukas; G H Growe; M T Schechter; R W Palmer; D N Lawrence
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

3.  A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam.

Authors:  E J Van Ameijden; J A Van den Hoek; G H Mientjes; R A Coutinho
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

4.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.

Authors:  P Simmonds; P Balfe; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Productive human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient.

Authors:  D Mathez; D Paul; C de Bélilovsky; Y Sultan; J Deleuze; I Gorin; W Saurin; R Decker; J Leibowitch
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Antibodies against the major core protein p24 of human immunodeficiency virus: relation to immunological, clinical and prognostic findings.

Authors:  B O Lindhardt; J Gerstoft; B Hofmann; G Pallesen; L Mathiesen; E Dickmeiss; K Ulrich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

7.  Association of human immunodeficiency virus (HIV) p24 antigenemia with decrease in CD4+ lymphocytes and onset of acquired immunodeficiency syndrome during the early phase of HIV infection.

Authors:  C Rinaldo; L Kingsley; J Neumann; D Reed; P Gupta; D Lyter
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

8.  Direct detection of proviral gag segment of human immunodeficiency virus in peripheral blood lymphocytes by colorimetric PCR assay as a clinical laboratory tool applied to different at-risk populations.

Authors:  F Pane; S Buttò; M L Gobbo; M Franco; C Butteroni; L Pastore; G Maiorano; M Foggia; P T Cataldo; A Guarino
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.

Authors:  L M Aledort; M W Hilgartner; M C Pike; G F Gjerset; M A Koerper; E Y Lian; J M Lusher; J W Mosley
Journal:  BMJ       Date:  1992-01-25

10.  Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.

Authors:  R Cheingsong-Popov; C Panagiotidi; S Bowcock; A Aronstam; J Wadsworth; J Weber
Journal:  BMJ       Date:  1991-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.